90 related articles for article (PubMed ID: 26181424)
1. Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma.
Modak S; Asante-Korang A; Steinherz LJ; Grana N
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e381-3. PubMed ID: 26181424
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.
Banks M; Crowell K; Proctor A; Jensen BC
Cardiovasc Toxicol; 2017 Oct; 17(4):487-493. PubMed ID: 28861837
[TBL] [Abstract][Full Text] [Related]
3.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
4. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
8. In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma.
Takeuchi Y; Tanaka T; Higashi M; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
J Pediatr Surg; 2018 Dec; 53(12):2454-2459. PubMed ID: 30266481
[TBL] [Abstract][Full Text] [Related]
9. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.
Leonard JT; Raess PW; Dunlap J; Hayes-Lattin B; Tyner JW; Traer E
J Hematol Oncol; 2016 Mar; 9():31. PubMed ID: 27036514
[TBL] [Abstract][Full Text] [Related]
10. Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma.
Kleemann J; Hrgovic I; Hempel K; Kaufmann R; Meissner M
Clin Exp Dermatol; 2018 Mar; 43(2):195-196. PubMed ID: 29023842
[No Abstract] [Full Text] [Related]
11. Ocular toxicity due to Trametinib and Dabrafenib.
Sarny S; Neumayer M; Kofler J; El-Shabrawi Y
BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062
[TBL] [Abstract][Full Text] [Related]
12. Anti-relapse effect of trametinib on a local minimal residual disease neuroblastoma mouse model.
Togashi Y; Tanaka T; Takemoto M; Takeuchi Y; Higashi M; Fumino S; Tajiri T
J Pediatr Surg; 2021 Jul; 56(7):1233-1239. PubMed ID: 33863557
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
Boull C; Hook K; Moertel C; Maguiness S
Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
[TBL] [Abstract][Full Text] [Related]
14. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
[TBL] [Abstract][Full Text] [Related]
15. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.
Giraud V; Longvert C; Houlle-Crepin S; Danel C; Labrune S; Camus P; Saiag P; Chinet T
BMC Cancer; 2015 Oct; 15():732. PubMed ID: 26481107
[TBL] [Abstract][Full Text] [Related]
16. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
17. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
18. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
19. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
20. Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy.
Toutain G; Min V; Rome A; Andre N
Pediatr Blood Cancer; 2022 Nov; 69(11):e29742. PubMed ID: 35652680
[No Abstract] [Full Text] [Related]
[Next] [New Search]
